These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 6405551

  • 1. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
    Paul E, Graef V, Ruppel R, Hellwich M.
    Z Hautkr; 1983 Feb 15; 58(4):262-5. PubMed ID: 6405551
    [Abstract] [Full Text] [Related]

  • 2. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G, Agrup P, Andersson T, Falck B, Hansson JA, Jacobsson S, Rorsman H, Rosengren E, Rosengren AM.
    Acta Derm Venereol; 1977 Feb 15; 57(2):113-6. PubMed ID: 71802
    [Abstract] [Full Text] [Related]

  • 3. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
    Paul E, Graef V, Ruppel R.
    Z Hautkr; 1980 Dec 01; 55(23):1543-60. PubMed ID: 6782780
    [Abstract] [Full Text] [Related]

  • 4. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
    Agrup G, Agrup P, Andersson T, Hafström L, Hansson C, Jacobsson S, Jönsson PE, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1979 Dec 01; 59(5):381-8. PubMed ID: 93360
    [Abstract] [Full Text] [Related]

  • 5. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
    Agrup G, Agrup P, Andersson T, Falck B, Hansson J-A, Jacobsson S, Rorsman H, Rosengrem A-M, Rosengren E.
    Acta Derm Venereol; 1975 Dec 01; 55(5):337-41. PubMed ID: 52967
    [Abstract] [Full Text] [Related]

  • 6. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
    Beyer C, Fiedler H, Wohlrab W, Wozniak KD.
    Dermatol Monatsschr; 1986 Dec 01; 172(9):541-4. PubMed ID: 3098590
    [No Abstract] [Full Text] [Related]

  • 7. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
    Morishima T, Tatsumi F, Fukada E, Saito M, Fujita M, Nagashima N, Hanawa S.
    Arch Dermatol Res; 1983 Dec 01; 275(2):76-9. PubMed ID: 6409012
    [Abstract] [Full Text] [Related]

  • 8. [Melanoma metabolites (proceedings)].
    Rorsman H.
    Lakartidningen; 1978 Dec 06; 75(49):4596-7. PubMed ID: 723347
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
    Agrup G, Hafström L, Jönsson PE, Rorsman H.
    Lakartidningen; 1978 Dec 06; 75(49):4599-600. PubMed ID: 364213
    [No Abstract] [Full Text] [Related]

  • 10. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
    Stewart RM, Miller S, Gunder M.
    Acta Derm Venereol; 1983 Dec 06; 63(2):97-101. PubMed ID: 6189350
    [Abstract] [Full Text] [Related]

  • 11. The urinary melanogen cysteinyldopa in melanoma and in suntanning: Australian experience.
    Nixon PF.
    Aust N Z J Surg; 1978 Feb 06; 48(1):17-21. PubMed ID: 276342
    [Abstract] [Full Text] [Related]

  • 12. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
    Ichihasi M, Mojamdar M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1981 Sep 06; 91(10):1045-9. PubMed ID: 6798247
    [No Abstract] [Full Text] [Related]

  • 13. [Urinary 5-S-cysteinyldopa levels in patients with malignant melanoma. Preliminary results].
    Césarini JP, Meunier M.
    Rev Prat; 1975 Nov 06; 25(51):4037-9. PubMed ID: 1209143
    [No Abstract] [Full Text] [Related]

  • 14. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.
    Agrup G, Andersson T, Falck B, Persson K, Rorsman H, Rosengren AM, Rosengren E.
    Acta Derm Venereol; 1975 Nov 06; 55(1):5-6. PubMed ID: 46673
    [Abstract] [Full Text] [Related]

  • 15. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
    Inoi T, Mojamdar M, Ichihashi M, Mishima Y.
    Nihon Hifuka Gakkai Zasshi; 1982 Sep 06; 92(10):1065-9. PubMed ID: 6821170
    [No Abstract] [Full Text] [Related]

  • 16. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
    Yamada K, Walsh N, Hara H, Jimbow K, Chen H, Ito S.
    Arch Dermatol; 1992 Apr 06; 128(4):491-4. PubMed ID: 1580656
    [Abstract] [Full Text] [Related]

  • 17. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
    Marnot D, Decaux F, Berthelot P, Kalis B, Jardillier JC, Warren L.
    Cancer Detect Prev; 1983 Apr 06; 6(1-2):303-10. PubMed ID: 6411338
    [Abstract] [Full Text] [Related]

  • 18. Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.
    Prota G, Rorsman H, Rosengren AM, Rosengren E.
    Experientia; 1977 Jun 15; 33(6):720-1. PubMed ID: 891724
    [No Abstract] [Full Text] [Related]

  • 19. Detection and quantitation of 5-S-cysteinyldopa in melanotic and amelanotic melanoma in comparison with nonpigment cell tumors and it's urinary excretion.
    Mojamdar M, Ichihashi M, Mishima Y.
    J Dermatol; 1979 Dec 15; 6(6):379-82. PubMed ID: 120380
    [No Abstract] [Full Text] [Related]

  • 20. Trichochromes in the urine of melanoma patients.
    Agrup G, Lindbladh C, Prota G, Rorsman H, Rosengren AM, Rosengren E.
    J Invest Dermatol; 1978 Feb 15; 70(2):90-1. PubMed ID: 621413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.